All In Biotech

Drug Trial Radar · NCT05919537

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations

Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Sep 6, 2023

Primary completion

Mar 1, 2031

Study completion Mar 1, 2031

Sponsor

Lead sponsor
Hummingbird BioscienceIndustry
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

Conditions

  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • HMBD-001Drug

    HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

  • DocetaxelDrug

    Docetaxel 75 mg/m\^2 IV once every 3 weeks

  • Nab-paclitaxelDrug

    Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

  • GemcitabineDrug

    Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Nature of Adverse Events (AEs)Time frame: From the time the ICF is signed until 30 days after last dose of study treatment
  2. Arm A and B only: Incidence and nature of dose-limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Arm A: During the first four weeks of study treatment Arm B: During the first three weeks of study treatment
  3. Objective Response Rate (ORR) by RECIST V1.1Time frame: Up to 24 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • GenesisCare North Shore

    Sydney, New South Wales, Australia

  • ICON Cancer Centre South Brisbane

    Brisbane, Queensland, Australia

  • Southern Oncology Clinical Research Unit

    Adelaide, South Australia, Australia

  • Cabrini Health

    Malvern, Victoria, Australia

  • Linear Clinical Research

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.